0001493152-22-020517.txt : 20220728 0001493152-22-020517.hdr.sgml : 20220728 20220728160602 ACCESSION NUMBER: 0001493152-22-020517 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220728 DATE AS OF CHANGE: 20220728 EFFECTIVENESS DATE: 20220728 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTRX CORP CENTRAL INDEX KEY: 0000799698 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581642750 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-408110 FILM NUMBER: 221115242 BUSINESS ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 BUSINESS PHONE: 310-826-5648 MAIL ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 D/A 1 primary_doc.xml X0708 D/A LIVE 0000799698 CYTRX CORP 11726 SAN VICENTE BOULEVARD SUITE 650 LOS ANGELES CA CALIFORNIA 90049 (310) 826-5648 DELAWARE None None Corporation true John Caloz 11726 San Vicente Boulevard Suite 650 Los Angeles CA CALIFORNIA 90049 Executive Officer Chief Financial Officer Stephen Snowdy 11726 San Vicente Boulevard Suite 650 Los Angeles CA CALIFORNIA 90049 Executive Officer Chairman and Chief Executive Officer Cary Claiborne 11726 San Vicente Boulevard Suite 650 Los Angeles CA CALIFORNIA 90049 Director Joel Caldwell 11726 San Vicente Boulevard Suite 650 Los Angeles CA CALIFORNIA 90049 Director Jennifer Simpson 11726 San Vicente Boulevard Suite 650 Los Angeles CA CALIFORNIA 90049 Director Pharmaceuticals Decline to Disclose 06b true 0001493152-21-018025 2021-07-13 true true true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 4TH FLOOR NEW YORK NY NEW YORK 10022 NY NEW YORK false 18240000 8240000 10000000 Represents 8,240 shares of Series C 10.00% Convertible Preferred Stock at $1,000 per share and preferred investment options ("PIOs") to purchase up to 11,363,637 shares of common stock, exercise price of $0.88 per share, initially sold on 7/13/2021. false 1 1281600 true 0 Consists of: $600,000 cash fee (6% of the aggregate gross proceeds), $75,000 in reimbursable non-accountable expenses, $6,600 in escrow fees and $600,000, the maximum additional cash fee payable to the Agent, subject to the exercise of PIOs for cash. 0 false CYTRX CORP /s/ John Caloz John Caloz Chief Financial Officer 2022-07-28